ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
November 13, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital...
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
November 09, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates Dr. Thaddeus (Ted) Dryja, a pioneer in the field of retinal genetic diseases, joins the Company’s Scientific Advisory Board.Dr. Dryja will play a key strategic role in the development and...
ProQR to Present at EuroTIDES Conference
October 31, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
October 24, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR to Present at the Chardan Inaugural Gene Therapy Conference
October 06, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Oct. 06, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
September 25, 2017 16:00 ET
|
ProQR Therapeutics N.V.
Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.A clinically meaningful improvement of CF respiratory...
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
September 21, 2017 07:05 ET
|
ProQR Therapeutics N.V.
Key updates ProQR presents in vivo data in a relevant disease model, establishing proof of concept for its novel and proprietary Axiomer® RNA editing platform technology.Axiomer® technology Editing...
ProQR to Present at Two Investor Conferences in September
September 21, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will present at two investor conferences during the month of...
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
August 28, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR appoints three new members to the Company’s Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong, who bring a tremendous amount of experience in the...